Prophylaxis and therapy of reactivation of hepatitis B in immunosuppressed patients;Prophylaxe und therapie der reaktivierung einer hepatitis B bei immunsuppression

Deutsche Medizinische Wochenschrift

Volumn 134, Issue 6, 2009, Pages 255-258

  Von Wagner, M ^a   Zeuzem, Stefan ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Hepatitis B; Immunosuppression; Prophylaxis; TACE

Indexed keywords

ADEFOVIR DIPIVOXIL; ALEMTUZUMAB; ALPHA INTERFERON; ANTHRACYCLINE; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HEPATITIS B VACCINE; INFLIXIMAB; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTINEOPLASTIC AGENT;

ANTIVIRAL THERAPY; BONE MARROW SUPPRESSION; CHEMOTHERAPY; CORTICOSTEROID THERAPY; DNA DETERMINATION; DRUG EFFICACY; HEPATITIS B; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; VIRUS DIAGNOSIS; VIRUS GENE; VIRUS REACTIVATION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HEPATITIS B VIRUS; IMMUNE DEFICIENCY; RECURRENT DISEASE; RISK FACTOR; VIRUS ACTIVATION;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; RECURRENCE; RISK FACTORS; VIRUS ACTIVATION;

EID: 60049086628     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0028-1123989     Document Type: Review

References (46)

1. Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999; 94: 249-251 (Pubitemid 29063477)
2. Al Taie OH, Mork H, Gassel AM et al. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature. Ann Hematol 1999; 78: 247-249 (Pubitemid 29259605)
3. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983-989 (Pubitemid 44133258)
4. Cheng AL, Hsiung CA, Su IJ et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320-1328 (Pubitemid 36667311)
5. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60
6. Cornberg M, Protzer U, Dollinger MM et al. Prophylaxe, Diagnotik und Therapie der Hepatitis-B-Virus-(HBV-) Infektion. AWMF-Register 021/011. Z Gastroenterol 2007; 45: 525-574
7. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69 (Pubitemid 32064857)
8. Dhedin N, Douvin C, Kuentz M et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998; 66: 616-619 (Pubitemid 28433844)
9. Esteve M, Saro C, Gonzalez-Huix F et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365 (Pubitemid 39120128)
10. Floreani A, Boninsegna S, Lobello S et al. Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal. Gastroenterol Clin Biol 2006; 30: 307-309
11. Fontaine H, Vallet-Pichard A, Chaix ML et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005; 80: 1086-1092 (Pubitemid 41611932)
12. Gartner BC, Jung W, Welsch C et al. Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation. J Clin Virol 2007; 38: 146-148 (Pubitemid 46091842)
13. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46: 328-346
14. Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68 (Pubitemid 44015749)
15. Iwai K, Tashima M, Itoh M et al. Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplant 2000; 25: 105-108
16. Jang JW, Choi JY, Bae SH et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004; 41: 427-435 (Pubitemid 39158752)
17. Jang JW, Choi JY, Bae SH et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006; 43: 233-240 (Pubitemid 43303991)
18. Knoll A, Boehm S, Hahn J et al. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 925-929 (Pubitemid 38660126)
19. Kumagai K, Takagi T, Nakamura S et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997; 8 Suppl 1: 107-109 (Pubitemid 27239442)
20. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696 (Pubitemid 36337972)
21. Lau GK, He ML, Fong DY et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702-709 (Pubitemid 34977182)
22. Lau GK, Lok AS, Liang RH et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997; 25: 1497-1501 (Pubitemid 27250775)
23. Lau GK, Suri D, Liang R et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002; 122: 614-624 (Pubitemid 34173812)
24. Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749 (Pubitemid 37500439)
25. Law JK, Ho JK, Hoskins P et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085-1089 (Pubitemid 40975032)
26. Liao CA, Lee CM, Wu HC et al. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002; 116: 166-169 (Pubitemid 34122076)
27. Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 1998; 13: 14-20
28. Lok AS, Liang RH, Chiu EK. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188
29. Meuleman P, Libbrecht L, Wieland S et al. Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol 2006; 80: 2797-2807 (Pubitemid 43346374)
30. Onozawa M, Hashino S, Izumiyama K et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616-619 (Pubitemid 40365894)
31. Ostuni P, Botsios C, Punzi L et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686-687 (Pubitemid 36760576)
32. Ozgonenel B, Moonka D, Savasan S. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma. Am J Hematol 2006; 81: 302-
33. Perceau G, Diris N, Estines O et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006; 155: 1053-1056 (Pubitemid 44564520)
34. Shibolet O, Ilan Y, Gillis S et al. Lamivudine therapy for prevention of immunosuppressive- induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391-396 (Pubitemid 34761098)
35. Tamori A, Nishiguchi S, Tanaka M et al. Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra-arterial chemotherapy for advanced hepatocellular carcinoma. Hepatol Res 2003; 26: 77-80 (Pubitemid 36939936)
36. Tsutsumi Y, Tanaka J, Kawamura T et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004; 83: 58-60 (Pubitemid 38088239)
37. Vizzini GB, Luca A, Marino IR. Hepatitis B virus reactivation after a single session of transarterial chemoembolization in patients with hepatocellular carcinoma. Ann Intern Med 2003; 138: 691-692 (Pubitemid 38124670)
38. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105-112
39. Westhoff TH, Jochimsen F, Schmittel A et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930- (Pubitemid 37022596)
40. Yamagata M, Murohisa T, Tsuchida K et al. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma 2007; 48: 431-433 (Pubitemid 46994901)
41. Yeo W, Chan PK, Ho WM et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-934 (Pubitemid 41103605)
42. Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307 (Pubitemid 30740118)
43. Yeo W, Ho WM, Hui P et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004; 88: 209-215 (Pubitemid 40137299)
44. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220 (Pubitemid 43303989)
45. Yeo W, Steinberg JL, Tam JS et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999; 59: 263-269 (Pubitemid 29468064)
46. Yeo W, Zee B, Zhong S et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311 (Pubitemid 38586252)